Zacks Investment Research upgraded shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a sell rating to a hold rating in a research report report published on Thursday morning.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

A number of other analysts have also issued reports on the stock. Piper Jaffray Companies restated an overweight rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Mizuho reaffirmed a buy rating and issued a $48.00 price objective (up previously from $26.00) on shares of Adamas Pharmaceuticals in a report on Tuesday, September 19th. Needham & Company LLC reaffirmed a buy rating and issued a $38.00 price objective on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. ValuEngine raised shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 1st. Finally, William Blair reaffirmed an ourperform rating on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $36.67.

Adamas Pharmaceuticals (ADMS) opened at 21.37 on Thursday. The stock has a 50 day moving average of $18.21 and a 200 day moving average of $17.22. The firm’s market cap is $481.12 million. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $23.84.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The firm’s quarterly revenue was down 90.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.78) EPS. On average, equities analysts forecast that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/25/adamas-pharmaceuticals-inc-adms-raised-to-hold-at-zacks-investment-research.html.

A number of institutional investors have recently added to or reduced their stakes in ADMS. Tower Research Capital LLC TRC acquired a new position in Adamas Pharmaceuticals in the second quarter worth $109,000. American International Group Inc. boosted its holdings in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 682 shares during the period. Virtu KCG Holdings LLC acquired a new position in Adamas Pharmaceuticals in the second quarter worth $184,000. Wells Fargo & Company MN boosted its holdings in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 3,358 shares during the period. Finally, Trexquant Investment LP acquired a new position in Adamas Pharmaceuticals in the first quarter worth $287,000. 69.24% of the stock is owned by hedge funds and other institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.